Welcome to our dedicated page for Oculis Holding Ordinary shares news (Ticker: OCS), a resource for investors and traders seeking the latest updates and insights on Oculis Holding Ordinary shares stock.
Oculis Holding AG (Nasdaq: OCS) is a leading global biopharmaceutical company dedicated to saving sight and enhancing eye care. Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is at the forefront of developing innovative treatments for serious eye diseases. The company's pipeline includes several promising candidates:
- OCS-01: A topical eye drop for diabetic macular edema (DME) and post-cataract surgery inflammation and pain. OCS-01 has shown compelling Phase 3 data, making it a potential new standard of care for these conditions.
- OCS-02: A topical biologic anti-TNFα eye drop for dry eye disease (DED) and non-infectious anterior uveitis. The OCS-02 RELIEF trial is in Phase 2b, with results eagerly anticipated.
- OCS-05: A neuroprotective candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders such as glaucoma and diabetic retinopathy. The ACUITY trial is set to provide critical data by the end of the year.
Oculis recently announced its fourth-quarter and full-year 2023 financial results, highlighted by positive Phase 3 data for OCS-01 and the commencement of three clinical trials, including OCS-02's RELIEF trial. The company is on track for a catalyst-rich 2024 with significant upcoming milestones, including readouts from the RELIEF trial in Q2 and the OPTIMIZE-2 and ACUITY trials in Q4. These milestones are crucial for Oculis' plan to submit its first New Drug Application (NDA).
Under the leadership of CEO Riad Sherif, M.D., Oculis has achieved remarkable progress and continues to advance its diversified pipeline. The company is backed by leading international healthcare investors and boasts a seasoned management team with a strong track record of success.
Financially, Oculis has reported significant strides, supported by both new and existing investors. The company has dual listings on Nasdaq in the U.S. and Iceland, reflecting its robust financial health and market confidence.
For more information, please visit Oculis Holding AG's website. For investor and media inquiries, contact Ms. Sylvia Cheung, CFO at sylvia.cheung@oculis.com or Corey Davis, Ph.D. at LifeSci Advisors at cdavis@lifesciadvisors.com.
Oculis has established its US headquarters in Boston, MA, enhancing its presence in the biotech hub as part of its strategy following its NASDAQ listing (OCS). This new office will facilitate operations and upcoming clinical milestones, including results from the Phase 3 DIAMOND study of OCS-01 for diabetic macular edema (DME) and the OPTIMIZE study for inflammation and pain post-cataract surgery later in 2023. Additionally, Oculis has bolstered its finance and development team with the hiring of Dr. Fang Li as Senior Vice President of Regulatory Affairs, who brings over 25 years of experience in drug approvals in ophthalmology. Oculis aims to leverage Boston's innovation ecosystem to support its operations and clinical development.
Oculis Holding AG (Nasdaq: OCS) announced management participation in two key investor conferences in April 2023. The first is the 22nd Annual Needham Virtual Healthcare Conference on April 20, where they will present from 8:45 to 9:25 AM ET. A live webcast will be available on the Oculis website. The second event is the 16th Annual Kempen Life Sciences Conference in Amsterdam, scheduled for April 25, 2023, featuring investor meetings. Oculis focuses on innovative treatments for eye care, with a pipeline that includes candidates for diabetic macular edema and dry eye disease.
Oculis Holding AG (Nasdaq: OCS) will hold a virtual conference call on April 13, 2023, from 8:00 am to 9:00 am ET to discuss its late-stage pipeline and clinical milestones. The company focuses on addressing significant medical needs in eye care, particularly in diabetic macular edema and dry eye disease. Oculis expects Stage 1 results from its Phase 3 DIAMOND study of OCS-01 later this year and plans to initiate two Phase 2 studies of OCS-02. Leading retina and anterior segment experts will participate in a Q&A session. A live audio webcast will be available on the company's website, with replay access for 30 days post-event.
Oculis Holding AG (NASDAQ: OCS) has completed enrollment in its Phase 3 OPTIMIZE trial for OCS-01, a novel topical corticosteroid aimed at treating inflammation and pain post-ocular surgery. The trial involves 240 patients at 25 locations in the U.S., focusing on reducing inflammation by Day 15 and pain by Day 4. If approved, OCS-01 could be the first once-daily, preservative-free corticosteroid for this purpose. Additional results from the Phase 3 DIAMOND trial for diabetic macular edema (DME) are also anticipated later this year, hinting at further advancements in ocular treatments.
FAQ
What is the current stock price of Oculis Holding Ordinary shares (OCS)?
What is the market cap of Oculis Holding Ordinary shares (OCS)?
What is Oculis Holding AG?
What products are in Oculis' pipeline?
Where is Oculis headquartered?
What recent achievements has Oculis made?
Who leads Oculis Holding AG?
What are the upcoming milestones for Oculis in 2024?
How did Oculis perform financially in 2023?
What conditions does OCS-01 treat?
What is the OCS-02 RELIEF trial?
How can I contact Oculis for investor or media inquiries?
